Drug intelligence / Profile preview

Hao Qin Xiao Zhi Fang

Development stage: Unknown
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Hao Qin Xiao Zhi Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), particularly targeting the "damp-heat accumulation" pattern according to TCM diagnostic principles. The formula aims to reduce hepatic fat accumulation and improve metabolic parameters such as lipid profiles and insulin sensitivity. It is currently being evaluated in a Phase 0 clinical trial to assess its efficacy and safety compared to lifestyle guidance alone, using controlled attenuation parameter (CAP) via FibroScan to quantify changes in liver steatosis over a 12-week period.

Other names: Haoqin Xiaozhi FormulaHaoqin Xiaozhi DecoctionHao Qin Xiao Zhi Fang

Beyond the preview

Go deeper on Hao Qin Xiao Zhi Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hao Qin Xiao Zhi Fang.